Di Ai
Overview
Explore the profile of Di Ai including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
46
Citations
590
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Assaye T, Abunimer L, Calisi N, Ai D
Cureus
. 2025 Mar;
17(2):e78390.
PMID: 40046370
Vascular tumors rarely occur in the breast, with hemangiomas being the most common benign form. The vast majority of these lesions occur in women and are clinically asymptomatic and non-palpable...
2.
Cui Z, Fu C, Ai D, Zhu H, Wang F, An X, et al.
FASEB J
. 2025 Mar;
39(5):e70444.
PMID: 40035540
As the first acetylated nucleoside to be discovered, N-acetyltransferase 10 (NAT10)-catalyzed RNA N4-acetylcytidine (acC) modification is involved in the occurrence of various diseases. However, the roles of RNA acC in...
3.
Ai D, Arrey E, Postlewait L, Gao Y, Li X
Histopathology
. 2025 Feb;
PMID: 39904575
Aims: Evaluation of pathological complete response (pCR) [no residual invasive carcinoma in the breast (RIC) or lymph node metastases (LNM) in surgical specimens following therapy] is typically based on evaluation...
4.
Zhang J, Li Z, Liu G, Yao W, Ai D, Li Z, et al.
Transl Pediatr
. 2025 Jan;
13(12):2110-2117.
PMID: 39823014
Background: The production of inhibitors is a serious complication that can arise during coagulation factor replacement therapy for hemophilia A (HA). The primary therapeutic strategy to eliminate inhibitors is immune...
5.
Mao Q, Chen Z, Liu G, Li G, Zhen Y, Cheng X, et al.
Pediatr Investig
. 2024 Dec;
8(4):244-252.
PMID: 39720280
Importance: Emicizumab (EMI) is efficacious and safe for hemophilia A (HA) prophylaxis. However, its high cost poses a challenge in China. Objective: To explore the possibility of using reduced-dosage EMI...
6.
Zhou Y, Li Z, Liu G, Chen Z, Yao W, Li G, et al.
Clin Ther
. 2024 Oct;
46(12):1010-1015.
PMID: 39419689
Background: It is still being determined if prophylaxis (PR) has superior cost effectiveness compared with on-demand (OD) treatment for moderate or severe hemophilia A (HA) children in China. Objective/purpose: To...
7.
Yao W, Ai D, Zhang Q, Li X, Zhou M, Zhang N, et al.
Thromb Res
. 2024 Aug;
241:109110.
PMID: 39116483
Background: The Chinese Haemophilia Individualized Prophylaxis Study (CHIPS), which was launched in 2016, reported a significant reduction in haemarthrosis over a one-year study. However, its long-term efficacy requires verification. This...
8.
An J, Zhao L, Cao Y, Ai D, Li M, You C, et al.
Plant Cell
. 2024 Jun;
36(10):4404-4425.
PMID: 38917246
Although the strigolactone (SL) signaling pathway and SL-mediated anthocyanin biosynthesis have been reported, the molecular association between SL signaling and anthocyanin biosynthesis remains unclear. In this study, we identified the...
9.
Li Z, Sun J, Li Z, Chen Z, Liu G, Yao W, et al.
Pediatr Investig
. 2024 Jun;
8(2):91-100.
PMID: 38910855
Importance: It remained unclear that the efficacy comparison between low-dose immune tolerance induction (LD-ITI) incorporating immunosuppressants (IS) when severe hemophilia A (SHA) patients had inhibitor-titer ≥200 Bethesda Units (BU)/mL (LD-ITI-IS...
10.
Ai D, Zhao L, You C, Han Y, An J
J Integr Plant Biol
. 2024 Jun;
66(7):1270-1273.
PMID: 38888226
The E3 ubiquitin ligase MdSINA11 targets the jasmonate ZIM domain protein MdJAZ2 for ubiquitination and degradation through the 26S proteasome pathway, thereby initiating jasmonate signaling and jasmonic acid-triggered anthocyanin biosynthesis...